Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | US$693.83B | 62.4x | 0.78 | US$772.87 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.5% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | US$373.59B | 17.1x | -0.42 | US$155.27 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.7% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | US$330.56B | 79.9x | -2.65 | US$187.63 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.3% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | US$308.07B | 18.7x | 1.07 | US$69.32 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.1% Upside | Upgrade to Pro+ | |
UnitedHealth | NYSE | Healthcare | Healthcare Providers & Services | US$275.08B | 12.6x | 0.28 | US$303.71 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.4% Upside | Upgrade to Pro+ | |
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | US$258.61B | 26.4x | -0.9 | US$40.32 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.4% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | US$258.61B | 26.4x | -0.9 | US$323.13 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | OTC Markets | Healthcare | Pharmaceuticals | US$240.07B | 19.1x | -1.41 | US$121.60 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | US$240.07B | 19.1x | -1.41 | US$122.12 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -9.9% Downside | Upgrade to Pro+ | |
Abbott Labs | NYSE | Healthcare | Healthcare Equipment & Supplies | US$232.62B | 17.2x | 0.12 | US$133.70 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7% Upside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | US$215.79B | 27.9x | 1.24 | US$142.63 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | US$215.79B | 27.9x | 1.24 | US$69.63 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.5% Upside | Upgrade to Pro+ | |
Merck&Co | NYSE | Healthcare | Pharmaceuticals | US$203.14B | 11.8x | 0.02 | US$80.90 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23% Upside | Upgrade to Pro+ | |
Intuitive Surgical | NASDAQ | Healthcare | Healthcare Equipment & Supplies | US$191.65B | 76.9x | 3.38 | US$534.71 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.9% Upside | Upgrade to Pro+ | |
Thermo Fisher Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$158.06B | 24.5x | 2.66 | US$418.70 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.7% Upside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | US$157.52B | 26.5x | 0.48 | US$292.95 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
Boston Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$153.21B | 75x | 4.99 | US$103.83 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
Stryker | NYSE | Healthcare | Healthcare Equipment & Supplies | US$150B | 52.2x | -3.41 | US$392.51 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.8% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | US$143.33B | 18.2x | 0.01 | US$25.24 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.9% Upside | Upgrade to Pro+ | |
Danaher | NYSE | Healthcare | Healthcare Equipment & Supplies | US$142.87B | 38.4x | -3.07 | US$199.63 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.7% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | US$139.05B | 23.3x | 0.02 | US$111.78 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6% Upside | Upgrade to Pro+ | |
Essilor International SA | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$128.26B | 45.5x | 46.46 | US$138.46 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.9% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | US$117.95B | 16.5x | 0.41 | US$48.32 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.7% Upside | Upgrade to Pro+ | |
Vertex | NASDAQ | Healthcare | Pharmaceuticals | US$117.93B | -112.4x | 0.96 | US$459.41 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.6% Upside | Upgrade to Pro+ | |
Medtronic | NYSE | Healthcare | Healthcare Equipment & Supplies | US$112.35B | 24.1x | 0.79 | US$87.67 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | US$94.61B | 17.4x | 0.09 | US$46.49 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.4% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | US$91.99B | 28.2x | 1.84 | US$735.33 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.8% Upside | Upgrade to Pro+ | |
HCA | NYSE | Healthcare | Healthcare Providers & Services | US$91.17B | 16.6x | 1.28 | US$378.98 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.2% Upside | Upgrade to Pro+ | |
CVS Health Corp | NYSE | Healthcare | Healthcare Providers & Services | US$84.35B | 15.9x | -0.61 | US$66.68 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Cigna | NYSE | Healthcare | Healthcare Providers & Services | US$83.50B | 17.1x | 0.37 | US$313.63 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.4% Upside | Upgrade to Pro+ |